News
Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s dise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback